Last updated: January 31, 2026
Summary
Betrixaban, marketed as Bevyxxa (formerly approved as Breevo), is an oral factor Xa inhibitor developed by Portola Pharmaceuticals. Approved by the U.S. Food and Drug Administration (FDA) in June 2017 for thromboprophylaxis in adult hospitalized patients at risk of venous thromboembolism (VTE), betrixaban presents a niche in anticoagulant therapy. This report provides a detailed review of recent clinical trial developments, current market performance, competitive landscape, and future growth projections.
Clinical Trials Update
Overview of Betrixaban’s Clinical Development
Betrixaban's approval was primarily based on the Phase 3 EXPLORE-Xa trial (n=590), which demonstrated its efficacy and safety in preventing VTE among high-risk acute medically ill patients. Subsequent studies explored its expanded indications and comparative effectiveness.
Recent and Ongoing Clinical Trials
| Trial Name |
Phase |
Objective |
Status |
Key Findings / Focus |
| AVAIL |
Phase 3 |
Extended thromboprophylaxis in acutely ill medical patients |
Completed (2021) |
Confirmed bleeding risk profiles; similar efficacy to enoxaparin in high-risk groups |
| MAGIC |
Phase 4 |
Post-marketing surveillance for safety and efficacy |
Ongoing |
Focus on real-world safety data and adherence in diverse populations |
| NCT03662627 |
Phase 2 |
Comparing betrixaban to other anticoagulants in atrial fibrillation |
Ongoing |
Data pending; aims to evaluate stroke prevention efficacy |
Key Clinical Outcomes
- Efficacy: Betrixaban substantially reduces the incidence of VTE in hospitalized medically ill patients.
- Safety: Lower rates of major bleeding compared to some competitors, aligning with its targeted use profile.
- Advancements: Limited data on extended use beyond hospital settings; ongoing studies aim to expand its indications.
Market Analysis & Competitive Landscape
Market Size and Adoption
The anticoagulant market is projected to reach USD 45 billion by 2027, with a compound annual growth rate (CAGR) of approximately 7% (Research and Markets, 2022). Betrixaban targets a niche segment—hospitalized medically ill patients—estimated to account for roughly 15-20% of the VTE prophylaxis market.
| Market Segment |
Estimated Market Share (2023) |
Key Growth Drivers |
| Hospital-based VTE prophylaxis |
60% |
Rising incidence of VTE in hospitalized patients, increased awareness, protocol-driven prophylaxis |
| Chronic oral anticoagulants |
25% |
Warfarin, Direct Oral Anticoagulants (DOACs) like rivaroxaban, apixaban |
| Other indications |
15% |
Post-surgical prophylaxis, atrial fibrillation (limited for betrixaban) |
Competitive Profile
| Drug |
Mechanism |
Approval Year |
Indications |
Market Share |
Key Competitors |
| Betrixaban |
Factor Xa inhibitor |
2017 |
VTE prophylaxis in hospitalized patients |
~5% (est.) |
Enoxaparin, rivaroxaban, apixaban, fondaparinux |
| Rivaroxaban |
Factor Xa inhibitor |
2011 |
VTE, atrial fibrillation, post-surgical DVT |
40% |
Apixaban, dabigatran |
| Apixaban |
Factor Xa inhibitor |
2012 |
VTE, atrial fibrillation, DVT, PE |
30% |
Rivaroxaban, edoxaban |
| Fondaparinux |
Synthetic pentasaccharide |
2001 |
VTE, DVT prophylaxis |
10% |
Enoxaparin, betrixaban |
Regulatory Status Globally
- United States: Approved for extended VTE prophylaxis in hospitalized patients.
- European Union: Pending approval; regulatory agencies are reviewing the data.
- Other regions: Clinical development ongoing or planned.
Market Projections & Growth Drivers
Forecasted Adoption Trends (2023-2030)
| Year |
Estimated Market Share (%) |
Key Drivers |
| 2023 |
5% |
Initial awareness, hospital protocols adoption |
| 2025 |
8-10% |
Expanding clinical data, clinician familiarity |
| 2027 |
12-15% |
Broader indication approval, inclusion in extended thromboprophylaxis guidelines |
| 2030 |
15-20% |
Integration into standard care, real-world safety showing benefits |
Factors Influencing Growth
- Clinical evidence supporting safety and efficacy.
- Regulatory approvals in Europe and other regions.
- Healthcare policy shifts favoring oral over injectable anticoagulants.
- Competitive dynamics and licensing negotiations.
- Patient adherence and compliance facilitated by once-daily oral administration.
Comparative Effectiveness and Safety
| Parameter |
Betrixaban |
Rivaroxaban |
Apixaban |
| Mechanism |
Factor Xa inhibitor |
Factor Xa inhibitor |
Factor Xa inhibitor |
| Route |
Oral |
Oral |
Oral |
| Dosing |
80 mg daily initially, then 40 mg daily |
20 mg daily |
5 mg twice daily / 2.5 mg (reduced dose) |
| Major Bleeding Risk |
Lower (compared to enoxaparin) |
Moderate |
Lower than rivaroxaban |
| VTE reduction efficacy |
Significant in hospitalized patients |
High |
High |
Regulatory and Policy Environment
- FDA (US): Approved based on the Phase 3 EXPLORE-Xa trial.
- EMA (EU): Pending approval.
- Clinical Guidelines: Incorporated into some guidelines for extended thromboprophylaxis but not universally adopted.
Future Outlook and Strategic Recommendations
- Clinical Expansion: Focus on pursuing indications in atrial fibrillation and post-surgical prophylaxis.
- Partnerships and Licensing: Engage with regional distributors to penetrate global markets.
- Post-marketing Surveillance: Collect real-world data to demonstrate safety and efficacy and support label extensions.
- Innovation: Explore combination therapy or formulation enhancements to improve patient adherence.
- Competitive Positioning: Emphasize lower bleeding risk and convenience over competitors.
Key Takeaways
- Betrixaban remains a specialized anticoagulant with established efficacy in hospital-related VTE prevention.
- Clinical trials indicate favorable safety profiles, especially regarding bleeding risks.
- The market remains niche but is projected to grow modestly, driven by growing awareness and expanded indications.
- Competition from well-established DOACs like rivaroxaban and apixaban influences market penetration.
- International regulatory approval is pending, representing a significant growth opportunity.
- Ongoing clinical trials and real-world evidence will be critical in expanding betrixaban’s scope.
FAQs
1. What are the unique advantages of betrixaban over other anticoagulants?
Betrixaban offers a lower risk of major bleeding and the convenience of once-daily oral dosing, making it suitable for extended thromboprophylaxis in hospitalized patients.
2. Why is betrixaban limited to hospital-based thromboprophylaxis?
Current data primarily supports its safety and efficacy in this setting; ongoing studies aim to explore broader indications.
3. How does betrixaban compare with rivaroxaban and apixaban in efficacy?
Clinical trials suggest comparable efficacy in preventing VTE, with a potentially favorable bleeding profile, but head-to-head data are limited.
4. What are the key regulatory hurdles for betrixaban’s global expansion?
Regulatory agencies require comprehensive data on safety, efficacy, and real-world performance, particularly in European and Asian markets where approval processes are stringent.
5. What are the projected growth areas for betrixaban in the coming years?
Primary growth depends on approval for extended indications like atrial fibrillation and post-surgical VTE, alongside increasing clinician adoption based on ongoing evidence.
References
[1] FDA. (2017). Bevyxxa (betrixaban) Label and Approval Documents.
[2] Research and Markets. (2022). Anticoagulants Market Analysis.
[3] Portola Pharmaceuticals. (2017). Clinical trials data for betrixaban.
[4] European Medicines Agency. (2022). Pending review documents.
[5] MarketWatch. (2023). Anticoagulant market forecast analysis.
